<DOC>
	<DOCNO>NCT01506479</DOCNO>
	<brief_summary>The purpose study learn effect exercise patient recently diagnose Parkinson 's disease ( PD ) . The investigator go test two level exercise ( moderate vigorous ) exercise . The investigator think exercise may reduce symptom PD , investigator hope learn level exercise offer benefit .</brief_summary>
	<brief_title>Study Parkinson 's Disease Exercise</brief_title>
	<detailed_description>The overall objective Phase II study determine futility non-futility conduct Phase III randomize control trial determine effect exercise progression PD symptom . The primary aim determine whether individual de novo Parkinson 's disease ( na√Øve drug treatment ) achieve randomly assign level mean exercise intensity ( 60-65 % HRmax 80-85 % HRmax ) adhere exercise protocol .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Clinical diagnosis primary Parkinson 's disease In Hoehn Yahr stage less stage III Disease duration le 5 year Not likely require dopaminergic therapy within 6 month Use PD medication within 60 day prior begin study , include levodopa , direct dopamine agonist , amantadine , Rasagiline ( Azilect ) , Selegiline ( Eldepryl ) , Artane ( trihexyphenidyl ) . Duration previous use medication PD exceed 90 day Expected require dopaminergic therapy next 6 month Poorly control unstable cardiovascular disease Uncontrolled hypertension Hypo hyperthyroidism , abnormal liver function , abnormal renal function Mild cognitive impairment ( Montreal Cognitive Assessment score &lt; 26/30 ) Depression preclude ability exercise ( Beck depression score &gt; 13 ) Disorders interfere ability perform endurance exercise Regular participation vigorous endurance exercise Evidence serious arrhythmia ischemic heart disease Any clinically significant medical condition , psychiatric condition , drug alcohol abuse , laboratory abnormality would , judgment investigator , interfere ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>Basal Ganglia Disease</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Movement Disorders</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Brain Diseases</keyword>
</DOC>